Sweden's Isconova buys Nordic Vaccine

Isconova has purchased the Danish drug delivery and adjuvants company Nordic Vaccine for over 4 million Swedish kroner, or $663,000. "The acquisition of Nordic Vaccine is in line with Isconova's strategy to take part in the ongoing market consolidation. With the acquired patents we will strengthen our commercial opportunities and patent family within iscom and Matrix-technologies," Isconova CEO Lena Söderström said in a release.

Nordic Vaccines has similar vaccine delivery technologies as Isconova's in its portfolio, as well as a needle-free patch delivery technology that is in preclinical testing. Isconova's adjuvants are used in various bovine and equine vaccines that are manufactured by Pfizer and Merck.

- check out the Isconova release

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.

Takeda has spent considerable resources on its phase 3 dengue vaccine, and now data show the shot was 80% effective in preventing dengue.